B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis
The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-19) and granulocyte homeostasis. Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressi...
Gespeichert in:
| Veröffentlicht in: | Blood 2005-08, Vol.106 (3), p.795-802 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 802 |
|---|---|
| container_issue | 3 |
| container_start_page | 795 |
| container_title | Blood |
| container_volume | 106 |
| creator | Dunleavy, Kieron Hakim, Frances Kim, Hyun Kyung Janik, John E. Grant, Nicole Nakayama, Takayuki White, Therese Wright, George Kwak, Larry Gress, Ronald Tosato, Giovanna Wilson, Wyndham H. |
| description | The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-19) and granulocyte homeostasis. Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressive B-cell lymphoma receiving DA-EPOCH (dose-adjusted etoposide, prednisone, Oncovin [vincristine], cyclophosphamide, and hydroxydaunorubicin) chemotherapy with or without rituximab. All patients were in remission and had no known causes for neutropenia. LON occurred in 6 (8%) of 76 patients receiving rituximab and 0 of 54 patients not receiving rituximab (P = .04). The median onset was 175 days (range, 77-204 days) after treatment with a median duration of 14 days (range, 11-16 days). In a subset of 24 patients, a significant correlation was found between rapid B-cell recovery and granulocyte decline over the 6-month recovery period (R = –0.53; P = .04). Rapid B-cell recovery directly correlated with prerecovery SDF-1 levels (R = 0.65; P = .015) and SDF-1 decline (R = –0.67; P = .013) after recovery. Our results suggest that early B-cell lymphopoiesis is important for B-cell recovery following rituximab, and that perturbation of SDF-1 during B-cell recovery retards neutrophil egress from the bone marrow. These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis. |
| doi_str_mv | 10.1182/blood-2004-08-3198 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1895166</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712053190X</els_id><sourcerecordid>15718416</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-7022c539eab385dfd40f8e91f75ec6f91253b368955a028b9726994a8678395a3</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhi1ERUPhBTggXzi62N71ri0hJFpRqFSJC5ytWe9sYuSsI9tJySvw1HVIROHSkyX7m98z8xHyRvBLIbR8P4QYRyY5bxnXrBFGPyMLoaRmnEv-nCw45x1rTS_Oycucf3Iu2kaqF-RcqF7oVnQL8vuKOQyBJnRxh2lPpxhCvPfzkiZftr_8GgY2QMaRlhUm2OypzxRyjs5Dqbf3vqzoBlPZpgGKj3Omfqa5pLiGQEdMflepCVyJiQkK80iXCeZtiG5fkK7iGmMukH1-Rc4mCBlfn84L8uPm8_frr-zu25fb6093zLW6KaznUjrVGISh0WqcxpZPGo2YeoWum4yQqhmaThulgEs9mF52xrSgu143RkFzQT4eczfbYY2jw7kkCHaT6qxpbyN4-__L7Fd2GXdW1EzRdTVAHgNcijknnP7WCm4PZuwfM_ZgxnJtD2Zq0dt_f30sOamowLsTANlBmOqSnM-PXJ2bSyEq9-HIYd3RzmOy2XmcHY6-Six2jP6pPh4AF9SwkA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dunleavy, Kieron ; Hakim, Frances ; Kim, Hyun Kyung ; Janik, John E. ; Grant, Nicole ; Nakayama, Takayuki ; White, Therese ; Wright, George ; Kwak, Larry ; Gress, Ronald ; Tosato, Giovanna ; Wilson, Wyndham H.</creator><creatorcontrib>Dunleavy, Kieron ; Hakim, Frances ; Kim, Hyun Kyung ; Janik, John E. ; Grant, Nicole ; Nakayama, Takayuki ; White, Therese ; Wright, George ; Kwak, Larry ; Gress, Ronald ; Tosato, Giovanna ; Wilson, Wyndham H.</creatorcontrib><description>The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-19) and granulocyte homeostasis. Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressive B-cell lymphoma receiving DA-EPOCH (dose-adjusted etoposide, prednisone, Oncovin [vincristine], cyclophosphamide, and hydroxydaunorubicin) chemotherapy with or without rituximab. All patients were in remission and had no known causes for neutropenia. LON occurred in 6 (8%) of 76 patients receiving rituximab and 0 of 54 patients not receiving rituximab (P = .04). The median onset was 175 days (range, 77-204 days) after treatment with a median duration of 14 days (range, 11-16 days). In a subset of 24 patients, a significant correlation was found between rapid B-cell recovery and granulocyte decline over the 6-month recovery period (R = –0.53; P = .04). Rapid B-cell recovery directly correlated with prerecovery SDF-1 levels (R = 0.65; P = .015) and SDF-1 decline (R = –0.67; P = .013) after recovery. Our results suggest that early B-cell lymphopoiesis is important for B-cell recovery following rituximab, and that perturbation of SDF-1 during B-cell recovery retards neutrophil egress from the bone marrow. These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2004-08-3198</identifier><identifier>PMID: 15718416</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adult ; Aged ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-Lymphocytes - physiology ; Biological and medical sciences ; Chemokine CXCL12 ; Chemokines, CXC - blood ; Chemokines, CXC - physiology ; Clinical Observations, Interventions, and Therapeutic Trials ; Drug Evaluation ; Female ; Granulocytes - physiology ; Homeostasis ; Humans ; Immunotherapy ; Kinetics ; Lymphoma, B-Cell - complications ; Lymphoma, B-Cell - drug therapy ; Lymphopoiesis ; Male ; Medical sciences ; Middle Aged ; Neutropenia - chemically induced ; Neutropenia - etiology ; Pharmacology. Drug treatments ; Regeneration ; Retrospective Studies ; Rituximab</subject><ispartof>Blood, 2005-08, Vol.106 (3), p.795-802</ispartof><rights>2005 American Society of Hematology</rights><rights>2006 INIST-CNRS</rights><rights>Copyright © 2005, The American Society of Hematology 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-7022c539eab385dfd40f8e91f75ec6f91253b368955a028b9726994a8678395a3</citedby><cites>FETCH-LOGICAL-c483t-7022c539eab385dfd40f8e91f75ec6f91253b368955a028b9726994a8678395a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17020211$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15718416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dunleavy, Kieron</creatorcontrib><creatorcontrib>Hakim, Frances</creatorcontrib><creatorcontrib>Kim, Hyun Kyung</creatorcontrib><creatorcontrib>Janik, John E.</creatorcontrib><creatorcontrib>Grant, Nicole</creatorcontrib><creatorcontrib>Nakayama, Takayuki</creatorcontrib><creatorcontrib>White, Therese</creatorcontrib><creatorcontrib>Wright, George</creatorcontrib><creatorcontrib>Kwak, Larry</creatorcontrib><creatorcontrib>Gress, Ronald</creatorcontrib><creatorcontrib>Tosato, Giovanna</creatorcontrib><creatorcontrib>Wilson, Wyndham H.</creatorcontrib><title>B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis</title><title>Blood</title><addtitle>Blood</addtitle><description>The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-19) and granulocyte homeostasis. Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressive B-cell lymphoma receiving DA-EPOCH (dose-adjusted etoposide, prednisone, Oncovin [vincristine], cyclophosphamide, and hydroxydaunorubicin) chemotherapy with or without rituximab. All patients were in remission and had no known causes for neutropenia. LON occurred in 6 (8%) of 76 patients receiving rituximab and 0 of 54 patients not receiving rituximab (P = .04). The median onset was 175 days (range, 77-204 days) after treatment with a median duration of 14 days (range, 11-16 days). In a subset of 24 patients, a significant correlation was found between rapid B-cell recovery and granulocyte decline over the 6-month recovery period (R = –0.53; P = .04). Rapid B-cell recovery directly correlated with prerecovery SDF-1 levels (R = 0.65; P = .015) and SDF-1 decline (R = –0.67; P = .013) after recovery. Our results suggest that early B-cell lymphopoiesis is important for B-cell recovery following rituximab, and that perturbation of SDF-1 during B-cell recovery retards neutrophil egress from the bone marrow. These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-Lymphocytes - physiology</subject><subject>Biological and medical sciences</subject><subject>Chemokine CXCL12</subject><subject>Chemokines, CXC - blood</subject><subject>Chemokines, CXC - physiology</subject><subject>Clinical Observations, Interventions, and Therapeutic Trials</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Granulocytes - physiology</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kinetics</subject><subject>Lymphoma, B-Cell - complications</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphopoiesis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neutropenia - chemically induced</subject><subject>Neutropenia - etiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Regeneration</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFuEzEQhi1ERUPhBTggXzi62N71ri0hJFpRqFSJC5ytWe9sYuSsI9tJySvw1HVIROHSkyX7m98z8xHyRvBLIbR8P4QYRyY5bxnXrBFGPyMLoaRmnEv-nCw45x1rTS_Oycucf3Iu2kaqF-RcqF7oVnQL8vuKOQyBJnRxh2lPpxhCvPfzkiZftr_8GgY2QMaRlhUm2OypzxRyjs5Dqbf3vqzoBlPZpgGKj3Omfqa5pLiGQEdMflepCVyJiQkK80iXCeZtiG5fkK7iGmMukH1-Rc4mCBlfn84L8uPm8_frr-zu25fb6093zLW6KaznUjrVGISh0WqcxpZPGo2YeoWum4yQqhmaThulgEs9mF52xrSgu143RkFzQT4eczfbYY2jw7kkCHaT6qxpbyN4-__L7Fd2GXdW1EzRdTVAHgNcijknnP7WCm4PZuwfM_ZgxnJtD2Zq0dt_f30sOamowLsTANlBmOqSnM-PXJ2bSyEq9-HIYd3RzmOy2XmcHY6-Six2jP6pPh4AF9SwkA</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Dunleavy, Kieron</creator><creator>Hakim, Frances</creator><creator>Kim, Hyun Kyung</creator><creator>Janik, John E.</creator><creator>Grant, Nicole</creator><creator>Nakayama, Takayuki</creator><creator>White, Therese</creator><creator>Wright, George</creator><creator>Kwak, Larry</creator><creator>Gress, Ronald</creator><creator>Tosato, Giovanna</creator><creator>Wilson, Wyndham H.</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><general>The American Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20050801</creationdate><title>B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis</title><author>Dunleavy, Kieron ; Hakim, Frances ; Kim, Hyun Kyung ; Janik, John E. ; Grant, Nicole ; Nakayama, Takayuki ; White, Therese ; Wright, George ; Kwak, Larry ; Gress, Ronald ; Tosato, Giovanna ; Wilson, Wyndham H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-7022c539eab385dfd40f8e91f75ec6f91253b368955a028b9726994a8678395a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-Lymphocytes - physiology</topic><topic>Biological and medical sciences</topic><topic>Chemokine CXCL12</topic><topic>Chemokines, CXC - blood</topic><topic>Chemokines, CXC - physiology</topic><topic>Clinical Observations, Interventions, and Therapeutic Trials</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Granulocytes - physiology</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kinetics</topic><topic>Lymphoma, B-Cell - complications</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphopoiesis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neutropenia - chemically induced</topic><topic>Neutropenia - etiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Regeneration</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dunleavy, Kieron</creatorcontrib><creatorcontrib>Hakim, Frances</creatorcontrib><creatorcontrib>Kim, Hyun Kyung</creatorcontrib><creatorcontrib>Janik, John E.</creatorcontrib><creatorcontrib>Grant, Nicole</creatorcontrib><creatorcontrib>Nakayama, Takayuki</creatorcontrib><creatorcontrib>White, Therese</creatorcontrib><creatorcontrib>Wright, George</creatorcontrib><creatorcontrib>Kwak, Larry</creatorcontrib><creatorcontrib>Gress, Ronald</creatorcontrib><creatorcontrib>Tosato, Giovanna</creatorcontrib><creatorcontrib>Wilson, Wyndham H.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dunleavy, Kieron</au><au>Hakim, Frances</au><au>Kim, Hyun Kyung</au><au>Janik, John E.</au><au>Grant, Nicole</au><au>Nakayama, Takayuki</au><au>White, Therese</au><au>Wright, George</au><au>Kwak, Larry</au><au>Gress, Ronald</au><au>Tosato, Giovanna</au><au>Wilson, Wyndham H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>106</volume><issue>3</issue><spage>795</spage><epage>802</epage><pages>795-802</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>The occurrence of delayed neutropenia following rituximab is poorly defined and of unknown cause. We hypothesized it may be related to perturbations of stromal derived factor-1 (SDF-19) and granulocyte homeostasis. Late-onset neutropenia (LON) was investigated in 130 patients with untreated aggressive B-cell lymphoma receiving DA-EPOCH (dose-adjusted etoposide, prednisone, Oncovin [vincristine], cyclophosphamide, and hydroxydaunorubicin) chemotherapy with or without rituximab. All patients were in remission and had no known causes for neutropenia. LON occurred in 6 (8%) of 76 patients receiving rituximab and 0 of 54 patients not receiving rituximab (P = .04). The median onset was 175 days (range, 77-204 days) after treatment with a median duration of 14 days (range, 11-16 days). In a subset of 24 patients, a significant correlation was found between rapid B-cell recovery and granulocyte decline over the 6-month recovery period (R = –0.53; P = .04). Rapid B-cell recovery directly correlated with prerecovery SDF-1 levels (R = 0.65; P = .015) and SDF-1 decline (R = –0.67; P = .013) after recovery. Our results suggest that early B-cell lymphopoiesis is important for B-cell recovery following rituximab, and that perturbation of SDF-1 during B-cell recovery retards neutrophil egress from the bone marrow. These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>15718416</pmid><doi>10.1182/blood-2004-08-3198</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2005-08, Vol.106 (3), p.795-802 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1895166 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-Lymphocytes - physiology Biological and medical sciences Chemokine CXCL12 Chemokines, CXC - blood Chemokines, CXC - physiology Clinical Observations, Interventions, and Therapeutic Trials Drug Evaluation Female Granulocytes - physiology Homeostasis Humans Immunotherapy Kinetics Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Lymphopoiesis Male Medical sciences Middle Aged Neutropenia - chemically induced Neutropenia - etiology Pharmacology. Drug treatments Regeneration Retrospective Studies Rituximab |
| title | B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A49%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B-cell%20recovery%20following%20rituximab-based%20therapy%20is%20associated%20with%20perturbations%20in%20stromal%20derived%20factor-1%20and%20granulocyte%20homeostasis&rft.jtitle=Blood&rft.au=Dunleavy,%20Kieron&rft.date=2005-08-01&rft.volume=106&rft.issue=3&rft.spage=795&rft.epage=802&rft.pages=795-802&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2004-08-3198&rft_dat=%3Cpubmed_cross%3E15718416%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15718416&rft_els_id=S000649712053190X&rfr_iscdi=true |